This August 2020 photo provided by Dr. Se-Jin Lee shows a normal mouse and a “twice-muscled” mouse developed at the The Jackson Laboratory of the University of Connecticut School of Medicine in Farmington, Conn. Findings published on Monday, Sept. 7, 2020, show that muscle-bound mice, similar to the one pictured, held on to their bodybuilder-type physiques during a one month space mission. (Dr. Se-Jin Lee/University of Connecticut School of Medicine via AP)
By Marcia Dunn
Bulked-up, mutant "mighty mice" held onto their muscle during a monthlong stay at the International Space Station, returning to Earth with ripped bodybuilder physiques, scientists reported Monday.
The findings hold promise for preventing muscle and bone loss in astronauts on prolonged space trips like Mars missions, as well as people on Earth who are confined to a bed or need wheelchairs.
A research team led by Dr. Se-Jin Lee of the Jackson Laboratory in Connecticut sent 40 young female black mice to the space station in December, launching aboard a SpaceX rocket.
In a paper published in the Proceedings of the National Academy of Sciences, Lee said the 24 regular untreated mice lost considerable muscle and bone mass in weightlessness as expected — up to 18%.
But the eight genetically engineered "mighty mice" launched with double the muscle maintained their bulk. Their muscles appeared to be comparable to similar "mighty mice" that stayed behind at NASA's Kennedy Space Center.
In addition, eight normal mice that received "mighty mouse" treatment in space returned to Earth with dramatically bigger muscles. The treatment involves blocking a pair of proteins that typically limit muscle mass.
A SpaceX capsule brought all 40 mice back in good condition, parachuting into the Pacific off the California coast in January. Some of the ordinary mice were injected with the "mighty mice" drug after returning and quickly built up more muscle than their untreated companions, Lee said.
The scientists completed the experiment just as the coronavirus was hitting the U.S.
"The only silver lining of COVID is that we had time to write it up very intensively" and submit the results for publication, said Dr. Emily Germain-Lee of Connecticut Children's Medical Center, Lee's wife who also took part in the study. Both are affiliated with the University of Connecticut.
While encouraged by their findings, the couple said much more work needs to be done before testing the drug on people to build up muscle and bone, without serious side effects.
"We're years away. But that's how everything is when you go from mouse to human studies," Germain-Lee said.
Lee said the experiment pointed out other molecules and signaling pathways worth investigating — "an embarrassment of riches ... so many things we'd like to pursue." His next step: possibly sending more "mighty mice" to the space station for an even longer stay.
Three NASA astronauts looked after the space mice, performing body scans and injections: Christina Koch and Jessica Meir, who performed the first all-female spacewalk last fall, and Andrew Morgan. They are listed as co-authors.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
Vaccine maker Pfizer delayed its COVID shot for kids allegedly due to a lack of data on how it would perform against the omnicron variant, according to the Wall Street Journa. Peter Pitts, professor and founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner, joined Cheddar News Wrap to break down why the authorization can't be rushed. "Going forward, the FDA wants to look at data specifically against omicron, and it looks like that's going to be a three-shot regimen versus two, which was efficient against delta but not omicron because obviously omicron is more infectious," said Pitts.
Walker Ross, Assistant Professor of Sports Business Management at Florida Southern College, joins Business of Sports: The Beijing Winter Olympics 2022, where he says that actions Beijing and other Olympic host sites have been implementing to combat climate change has simply not been enough to offset their carbon footprint.
Bamboo-based toilet paper company Cloud Paper raised $5 million in a recent funding round. Its product is a bamboo-based alternative to traditional toilet paper made from trees, and its mission is to end the deforestation caused by traditional paper products. Cloud Paper says the raise will allow it to make significant investments in its supply chain, product development, and hiring. Ryan Fritsch, a co-founder of Cloud Paper, joined Cheddar News' Closing Bell to discuss.
Space tourism company World View plans to launch its first commercial flights in early 2024, with voyages to take off from iconic locations around the world like the Grand Canyon — but seemingly at a flexible price point. Dale Hipsh, president of tourism and exploration at World View, joined Cheddar to discuss what a trip to the stratosphere would look like with his company and its much less expensive take on space travel. "Our technology allows us to be more democratic, to offer more opportunities for people to experience near space, and that overview effect," he said. "So we're really thrilled to be bringing it to market."
A recent NOAA report found America's coastline could experience a century's worth of sea rise in just 30 years. By 2050, water on the U.S. coast will be 10-12 inches higher, causing major eastern cities to be hit regularly with floods, even on sunny days. Gary Mitchum, professor of physical oceanography at the University of South Florida, joins Cheddar News to discuss.
The Biden administration is launching a new task force to promote the use of 'cleaner' construction materials with lower life cycle emissions. This comes as the White House works to speed up government purchases of greener products. Sweta Chakraborty, climate change expert and U.S. president of "We Don't Have Time," joins Cheddar News to discuss.
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
On this episode of Cheddar Innovates: Evolution Devices CEO breaks down how the Evowalk wearable device can help those with walking impairments; Cresilon CEO explains how he's created a plant-based gel to easily treat wounds in both humans and animals; A look at Curiosity Stream's 'The Colorado Problem.'
Pier Mantovani, Founder and CEO of Evolution Devices, joins Cheddar Innovates to discuss how the Evowalk wearable device can help those with walking impairments, and how remote physical therapy is becoming a reality.
